

AMENDMENT TO THE CLAIMS:

Claim 1 (cancelled)

2. (Currently amended)) ~~The formulation of claim 1 wherein said one or more divalent metal ions comprises zinc or cobalt~~ A formulation comprising Apo-2 ligand and one or more divalent metal ions comprising zinc or cobalt, wherein the concentration of said one or more divalent metal ions present in the formulation is at a <2X molar ratio to said Apo-2 ligand and the Apo-2 ligand comprises a polypeptide selected from the group consisting of:

(a) a polypeptide having amino acid residues 1 to 281 of Figure 1 (SEQ ID NO:1);

(b) a polypeptide having amino acid residues 114 to 281 of Figure 1 (SEQ ID NO:1);

(c) a fragment of the polypeptide of (a) or (b) which induces apoptosis in at least one type of mammalian cell or binds an Apo-2 ligand receptor; and

(d) a polypeptide having at least 80% identity to the polypeptide of (a) or (b), and induces apoptosis in at least one type of mammalian cell or binds an Apo-2 ligand receptor.

3. (Original) The formulation of claim 2 wherein said one or more divalent ions comprises zinc.

4. (Original) The formulation of claim 3 wherein said zinc is selected from the group consisting of zinc chloride, zinc acetate, zinc sulfate, zinc carbonate and zinc citrate.

5. (Currently amended) The formulation of claim ~~1~~ 2 wherein said formulation is a pharmaceutically acceptable formulation.

6. (Currently amended) The formulation of claim ~~1~~ 2 wherein said Apo-2 ligand comprises amino acids 114 to 281 of Figure 1 (SEQ ID NO:1).

7. (Currently amended) The formulation of claim \pm 2 wherein said Apo-2 ligand comprises amino acids 1 to 281 of Figure 1 (SEQ ID NO:1).

8. (Currently amended) The formulation of claim \pm 2 wherein said formulation has a pH of about 6 to about 9.

9. (Original) The formulation of claim 8 wherein said formulation has a pH of about 7 to about 7.5.

10. (Currently amended) The formulation of claim \pm 2 wherein said formulation is an aqueous formulation.

11. (Currently amended) The formulation of claim \pm 2 wherein said formulation is a lyophilized formulation.

Claims 12-49 (Cancelled)

50. (Currently amended) ~~The formulation of claim 49 wherein said one or more divalent metal ions comprises zinc~~ A formulation comprising Apo-2 ligand and zinc, wherein the concentration of said zinc present in the formulation is at a <2X molar ratio to said Apo-2 ligand and the Apo-2 ligand comprises a polypeptide selected from the group consisting of:

(a) a polypeptide having amino acid residues 1 to 281 of Figure 1 (SEQ ID NO:1);

(b) a polypeptide having amino acid residues 114 to 281 of Figure 1 (SEQ ID NO:1);

(c) a fragment of the polypeptide of (a) or (b) which induces apoptosis in at least one type of mammalian cell or binds an Apo-2 ligand receptor; and

(d) a polypeptide having at least 80% identity to the polypeptide of (a) or (b), and induces apoptosis in at least one type of mammalian cell or binds an Apo-2 ligand receptor.

51. (Original) The formulation of claim 50 wherein said zinc is selected from the group consisting of zinc chloride, zinc acetate, zinc sulfate, zinc carbonate, and zinc citrate.

52. (Currently amended) The formulation of claim ~~49~~ 50 wherein said formulation has a pH of about 6 to about 9.

53. (Currently amended) The formulation of claim ~~49~~ 50 wherein said formulation has a pH of about 7 to about 7.5.

54. (Currently amended) The formulation of claim ~~49~~ 50 wherein said formulation is a lyophilized formulation.

Claims 55-60 (Cancelled)